Sagimet Biosciences Inc. (SGMT)

Sagimet Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	35.02	75.84	75.14	0.16	56.73
Short-Term Investments	78.1	75.41	19.76	32.19	-
Cash & Short-Term Investments	113.12	151.25	94.9	32.35	56.73
Cash Growth	-25.21%	59.38%	193.39%	-42.98%	-28.11%
Other Current Assets	3.28	1.52	1.75	0.45	1.93
Total Current Assets	116.4	152.77	96.65	32.79	58.66
Net Property, Plant & Equipment	0.08	0.08	0.07	0.21	0.34
Long-Term Investments	-	7.41	-	-	-
Other Long-Term Assets	-	-	-	0.03	0.03
Total Assets	116.48	160.26	96.72	33.03	59.03
Accounts Payable	1.31	1.43	0.19	1.13	0.76
Accrued Expenses	3.71	2.95	5.4	4.02	1.56
Current Portion of Leases	0.08	0.08	0.07	0.13	0.12
Total Current Liabilities	5.1	4.45	5.65	5.28	2.44
Long-Term Leases	-	-	-	0.08	0.22
Other Long-Term Liabilities	-	-	-	0	0.01
Total Long-Term Liabilities	-	-	-	0.08	0.23
Total Liabilities	5.1	4.45	5.65	5.36	2.67
Common Stock	0	0	0	0	0
Additional Paid-in Capital	457.61	450.88	340.78	35	33.11
Accumulated Other Comprehensive Income	0.12	0.23	0.03	-0.08	-
Retained Earnings	-346.35	-295.31	-249.74	-221.87	-191.37
Total Common Shareholders' Equity	111.38	155.81	91.07	-186.95	-158.26
Minority Interest	-	-	-	214.62	214.62
Shareholders' Equity	111.38	155.81	91.07	27.67	56.36
Total Liabilities & Equity	116.48	160.26	96.72	33.03	59.03
Total Debt	0.08	0.08	0.07	0.21	0.35
Net Cash (Debt)	113.05	151.17	94.83	32.13	56.38
Net Cash Growth	-25.22%	59.41%	195.11%	-43.01%	-28.05%
Net Cash Per Share	3.50	4.82	9.07	174.06	0.46
Book Value	111.38	155.81	91.07	-186.95	-158.26
Book Value Per Share	3.44	4.97	8.71	-1012.63	-1.29
Tangible Book Value	111.38	155.81	91.07	-186.95	-158.26
Tangible Book Value Per Share	3.44	4.97	8.71	-1012.63	-1.29

Updated Mar 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q